

TECHNICAL DATASHEET

PPARG polyclonal antibody

Cat. No. C15410133

| Type: Polyclonal | Specificity: Human, mouse | |
|--|--|--|
| Size: 50 µg/47 µl | Isotype: NA | |
| Concentration: 1.07 µg/µl | Host: Rabbit | |
| Lot No.: A576-001P | Purity: Affinity purified polyclonal antibody | |
| Storage buffer: PBS containing 0.05% azide and 0.05% ProClin 300. | Storage conditions: Store at -20°C; for long storage, store at -80°C. Avoid multiple freeze-thaw cycles. | |
| Precautions: This product is for research use only. Not for use in diagnostic or therapeutic procedures. | | |

Last Data Sheet Update: April 22, 2011

Description

Alternative names: PPAR-gamma, NR1C3

Polyclonal antibody raised in rabbit against human PPARG (peroxisome proliferator-activated receptor gamma), using a KLH-conjugated synthetic peptide containing a sequence from the central part of the protein.

Applications

| Applications | Suggested dilution | References |
|------------------|--------------------|--------------|
| ChIP * | 1 μg/ChIP | Fig 1 |
| ELISA | 1:1,000 | Fig 2 |
| Western Blotting | 1:2,000 | Fig 2, Ref 1 |

Please note that of the optimal antibody amount per IP should be determined by the end-user. We recommend testing 1-5 µg per IP.

Target Description

PPARG (UniProtKB/Swiss-Prot entry P37231) is a nuclear hormone receptor which binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Like many other nuclear hormone receptors, PPARG forms a heterodimer with the retinoid X receptor (RXR) leading to transcriptional regulation of various genes including acyl-CoA oxidase and cytochrome P450 A6. PPARG has been implicated in adipocyte differentiation and glucose homeostasis and in various diseases such as obesity, diabetes, atherosclerosis and cancer.

TECHNICAL DATASHEET

Validation data




Figure 1. ChIP results obtained with the Diagenode antibody directed against PPARG

ChIP was performed on macrophages derived from mouse bone marrow using the Diagenode antibody against PPARG (cat. No. CS-133-050) and optimized PCR primer sets for qPCR. Sheared chromatin from 1 million cells and 1 ?g of PPARg antibody were used per ChIP experiment. IgG was used as a negative IP control. Figure 1A: recovery, expressed as the % of input, of the PDK4 PPAR response element (RE). Figure 1B: recovery of the FABP4 Adipo PPAR RE in cells treated with RSG, a very strong activating ligand of PPARG, and in untreated cells.




Figure 2. Determination of the titer

To determine the titer, an ELISA was performed using a serial dilution of the Diagenode antibody directed against human PPARG (cat. No. CS-133-100). The plates were coated with the peptide used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 2), the titer of the antibody was estimated to be 1:70,250




Figure 3. Western blot analysis using the Diagenode antibody directed against PPARG

293T cells were transfected with pNTAP-PPARG and 20 ?g of protein extract was analysed by Western blot using the Diagenode antibody against PPARG (cat. No. CS-133-100). The antibody was diluted 1:2,000 in TBS-Tween containing 3% skimmed milk. Figure 2 shows the result of 293T cells transfected with pNTAP-PPARG (lane 1) and of non-transfected cells (lane 2). The position of the protein of interest is indicated on the right the marker (in kDa) is shown on the left.